Why Beam Therapeutics Jumped Today
Beam Therapeutics (NASDAQ: BEAM) was up 14% midday Monday on the back of Intellia Therapeutics' (NASDAQ: NTLA) phase 1 data for its therapy to treat a genetic liver disorder.
All of the companies associated with the gene-editing technique are having a good day thanks to the data. Although the treatment for the fatal disease -- transthyretin (ATTR) amyloidosis -- is great news, the implications go far beyond any one disease.
The results are the first to show the gene-editing approach known as CRISPR-Cas9 can be both safe and effective when performed in the human body. Previous applications used cells that had been removed, edited, and reinserted into the patient.
Source Fool.com
